Farmington-based LamdaVision is in the process of developing an effective method for restoring sight to millions with a potentially revolutionary protein-based artificial retina that will be surgically implanted in patients with age-related macular degeneration or retinitis pigmentosa. The company recently completed a successful series of proof-of-concept studies.

“It’s great to see your research turn into something that has the potential to actually help people,” says Nicole Wagner, Ph.D., the company’s president and CEO.